MeSH term
Frequency | Condition_Probility | Amino Acid Sequence | 10 | 0.0 |
Animals | 90 | 0.0 |
Cell Line | 20 | 0.0 |
DNA-Binding Proteins/*metabolism | 2 | 0.0 |
*Gene Expression Regulation, Developmental | 2 | 0.0 |
Humans | 256 | 0.0 |
Mice | 56 | 0.0 |
Molecular Sequence Data | 21 | 0.0 |
Promoter Regions (Genetics) | 2 | 0.0 |
Rats | 20 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 65 | 0.0 |
Transcription Factors/*metabolism | 4 | 0.0 |
*Transcription, Genetic | 3 | 0.0 |
Aged | 56 | 0.0 |
Aged, 80 and over | 17 | 0.0 |
Base Sequence | 19 | 0.0 |
Blotting, Northern | 6 | 0.0 |
Gene Expression Profiling | 2 | 0.0 |
Male | 135 | 0.0 |
Polymerase Chain Reaction | 10 | 0.0 |
Research Support, Non-U.S. Gov't | 137 | 0.0 |
United States | 2 | 0.0 |
Gene Expression | 3 | 0.0 |
Mice, Inbred BALB C | 3 | 0.0 |
Mice, Transgenic | 30 | 1.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 18 | 0.0 |
Age Factors | 7 | 0.0 |
Caspases/*metabolism | 2 | 0.0 |
Disease Models, Animal | 18 | 0.0 |
Female | 127 | 0.0 |
Immunohistochemistry | 13 | 0.0 |
Middle Aged | 94 | 0.0 |
Infant, Newborn | 8 | 0.0 |
Pregnancy | 2 | 0.0 |
Retrospective Studies | 14 | 0.0 |
Risk | 5 | 0.0 |
Survival Rate | 8 | 0.0 |
Age of Onset | 6 | 0.0 |
Blotting, Western | 7 | 0.0 |
Brain/*metabolism | 3 | 0.0 |
Brain Chemistry | 6 | 2.0 |
Comparative Study | 37 | 0.0 |
Huntington Disease/genetics/*metabolism | 3 | 75.0 |
Trinucleotide Repeat Expansion/genetics | 4 | 10.0 |
Adult | 90 | 0.0 |
Dose-Response Relationship, Drug | 8 | 0.0 |
Drug Interactions | 2 | 0.0 |
Germany | 2 | 0.0 |
Flow Cytometry | 4 | 0.0 |
Green Fluorescent Proteins | 2 | 0.0 |
Huntington Disease/genetics | 2 | 11.0 |
Macromolecular Substances | 2 | 0.0 |
Nerve Tissue Proteins/genetics | 11 | 4.0 |
Nuclear Proteins/genetics | 11 | 3.0 |
Peptides/genetics/*metabolism | 2 | 6.0 |
Transfection | 9 | 0.0 |
Sequence Deletion | 2 | 0.0 |
Disease Progression | 8 | 0.0 |
Huntington Disease/genetics/*metabolism/pathology | 3 | 60.0 |
Neurons/drug effects/metabolism/pathology | 2 | 28.0 |
Neuroprotective Agents/pharmacology | 4 | 11.0 |
PC12 Cells | 5 | 1.0 |
Mutation | 8 | 0.0 |
Protein Binding | 6 | 0.0 |
U937 Cells | 2 | 0.0 |
Caspases/metabolism | 3 | 0.0 |
Cell Death/*physiology | 2 | 5.0 |
Cells, Cultured | 13 | 0.0 |
In Situ Nick-End Labeling | 3 | 0.0 |
In Vitro | 4 | 0.0 |
Nerve Tissue Proteins/genetics/*metabolism | 9 | 6.0 |
Nuclear Proteins/genetics/*metabolism | 8 | 2.0 |
Brain/metabolism/pathology | 3 | 2.0 |
CHO Cells | 2 | 0.0 |
Hamsters | 6 | 0.0 |
Mice, Inbred C57BL | 6 | 0.0 |
Mice, Inbred CBA | 5 | 1.0 |
Microscopy, Immunoelectron | 2 | 0.0 |
*Mutation | 6 | 0.0 |
Peptides/genetics | 3 | 3.0 |
Recombinant Fusion Proteins/metabolism | 2 | 0.0 |
Transcription, Genetic | 2 | 0.0 |
Trinucleotide Repeat Expansion | 6 | 16.0 |
Adolescent | 35 | 0.0 |
Child | 25 | 0.0 |
Child, Preschool | 13 | 0.0 |
DNA, Neoplasm/analysis/genetics | 2 | 2.0 |
DNA-Binding Proteins/*genetics | 2 | 0.0 |
Predictive Value of Tests | 3 | 0.0 |
Recurrence | 2 | 0.0 |
DNA/genetics | 2 | 0.0 |
Gene Frequency | 6 | 0.0 |
Haplotypes | 3 | 0.0 |
Huntington Disease/*genetics | 15 | 36.0 |
Pedigree | 5 | 0.0 |
Trinucleotide Repeats/genetics | 3 | 4.0 |
Alleles | 10 | 0.0 |
Genetic Predisposition to Disease | 2 | 0.0 |
Genotype | 8 | 0.0 |
Linkage Disequilibrium | 2 | 0.0 |
Case-Control Studies | 8 | 0.0 |
Risk Factors | 5 | 0.0 |
Statistics | 2 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 8 | 0.0 |
Magnetic Resonance Spectroscopy | 2 | 0.0 |
RNA, Messenger/analysis | 5 | 0.0 |
Signal Transduction | 2 | 0.0 |
Apoptosis | 3 | 0.0 |
Biological Markers | 2 | 0.0 |
Corpus Striatum/metabolism | 2 | 8.0 |
Mitochondria/metabolism | 2 | 0.0 |
Models, Animal | 2 | 0.0 |
Oxidation-Reduction | 4 | 0.0 |
Oxidative Stress | 2 | 0.0 |
Cyclophosphamide/administration & dosage | 3 | 1.0 |
Doxorubicin/administration & dosage | 3 | 1.0 |
Drug Administration Schedule | 3 | 0.0 |
Salvage Therapy | 2 | 2.0 |
Treatment Outcome | 10 | 0.0 |
Vincristine/administration & dosage | 2 | 1.0 |
Cloning, Molecular | 4 | 0.0 |
Immunoblotting | 3 | 0.0 |
In Situ Hybridization | 2 | 0.0 |
Protein Structure, Tertiary | 3 | 0.0 |
RNA, Messenger/metabolism | 3 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 4 | 0.0 |
Sequence Homology, Amino Acid | 2 | 0.0 |
Exons/genetics | 3 | 0.0 |
Motor Activity | 2 | 4.0 |
Nerve Tissue Proteins/*genetics | 9 | 1.0 |
Nuclear Proteins/*genetics | 9 | 1.0 |
Phenotype | 11 | 0.0 |
Cause of Death | 2 | 1.0 |
Follow-Up Studies | 6 | 0.0 |
Brain/*metabolism/pathology | 2 | 2.0 |
Models, Biological | 3 | 0.0 |
Organ Specificity | 3 | 0.0 |
Solubility | 4 | 0.0 |
Abdomen/surgery | 2 | 14.0 |
Prospective Studies | 10 | 0.0 |
Huntington Disease/*genetics/metabolism | 2 | 50.0 |
Heart Rate/*physiology | 2 | 6.0 |
Leg/blood supply | 2 | 6.0 |
Time Factors | 15 | 0.0 |
Vascular Resistance/*physiology | 2 | 22.0 |
*Aging | 2 | 1.0 |
Dizocilpine Maleate/pharmacology | 2 | 11.0 |
*Cognition | 2 | 4.0 |
Severity of Illness Index | 4 | 0.0 |
Injections, Intravenous | 3 | 0.0 |
Cell Culture Techniques | 2 | 0.0 |
Mustard Gas/*toxicity | 5 | 62.0 |
Skin/pathology | 2 | 0.0 |
Epithelial Cells/drug effects | 2 | 6.0 |
DNA Primers | 3 | 0.0 |
RNA, Messenger/genetics/metabolism | 2 | 0.0 |
Brain/metabolism | 3 | 0.0 |
Models, Genetic | 2 | 0.0 |
Acyl-CoA Oxidase | 3 | 23.0 |
Dimerization | 2 | 0.0 |
Enoyl-CoA Hydratase/*genetics | 2 | 33.0 |
Peroxisome Proliferators/pharmacology | 2 | 16.0 |
Protein Binding/drug effects | 3 | 0.0 |
Pyrimidines/pharmacology | 2 | 1.0 |
Receptors, Cytoplasmic and Nuclear/*metabolism | 2 | 1.0 |
Receptors, Retinoic Acid/metabolism | 2 | 2.0 |
Retinoid X Receptors | 3 | 1.0 |
Substrate Specificity | 2 | 0.0 |
Disease-Free Survival | 2 | 0.0 |
Killer Cells, Natural/*immunology | 2 | 0.0 |
Recombinant Proteins/pharmacology | 2 | 0.0 |
Reference Values | 4 | 0.0 |
T-Lymphocytes/*immunology | 2 | 0.0 |
Calcium/blood | 2 | 0.0 |
Cross-Sectional Studies | 2 | 0.0 |
Echocardiography | 2 | 0.0 |
Potassium/blood | 2 | 2.0 |
*Renal Dialysis/adverse effects | 5 | 22.0 |
Reproducibility of Results | 2 | 0.0 |
*Renal Dialysis | 20 | 4.0 |
Prognosis | 3 | 0.0 |
Survival Analysis | 2 | 0.0 |
COS Cells | 3 | 0.0 |
Huntington Disease/*pathology | 3 | 50.0 |
DNA Primers/genetics | 2 | 0.0 |
DNA, Complementary/genetics | 2 | 0.0 |
Cellulose/analogs & derivatives | 2 | 6.0 |
Kidney Failure, Chronic/*physiopathology/*therapy | 2 | 66.0 |
*Membranes, Artificial | 2 | 2.0 |
*Peritoneal Dialysis, Continuous Ambulatory | 4 | 3.0 |
Densitometry, X-Ray | 2 | 1.0 |
English Abstract | 20 | 0.0 |
Kidney Failure, Chronic/complications/therapy | 2 | 7.0 |
Antibody Specificity | 3 | 0.0 |
Peptide Fragments/*metabolism | 2 | 1.0 |
Biopsy | 3 | 0.0 |
Renal Dialysis/*adverse effects | 6 | 4.0 |
Diagnosis, Differential | 4 | 0.0 |
Polymerase Chain Reaction/methods | 4 | 0.0 |
Transcription Factors/*genetics | 2 | 0.0 |
Tumor Cells, Cultured | 5 | 0.0 |
Transcription Factors/genetics/metabolism | 3 | 0.0 |
Trinucleotide Repeats/*genetics | 2 | 2.0 |
Magnetic Resonance Imaging | 3 | 0.0 |
*Nerve Tissue Proteins | 2 | 0.0 |
Neurons/metabolism/pathology | 2 | 2.0 |
Trinucleotide Repeat Expansion/*genetics | 2 | 3.0 |
Enzyme Activation | 3 | 0.0 |
Fluorescent Antibody Technique | 4 | 0.0 |
Malondialdehyde/blood | 2 | 3.0 |
Renal Dialysis | 10 | 3.0 |
Neoplasm Staging | 4 | 0.0 |
Huntington Disease/*metabolism/pathology | 2 | 33.0 |
Rabbits | 3 | 0.0 |
Biological Markers/blood | 4 | 0.0 |
Creatinine/blood | 2 | 0.0 |
Blood Urea Nitrogen | 3 | 5.0 |
Herpesvirus 4, Human/isolation & purification | 3 | 5.0 |
Hyperplasia | 2 | 0.0 |
Mice, Nude | 2 | 0.0 |
Feasibility Studies | 2 | 0.0 |
Glutamine/*genetics/metabolism | 2 | 100.0 |
Huntington Disease/genetics/metabolism | 2 | 100.0 |
Mice, Mutant Strains | 2 | 0.0 |
Oxidoreductases/genetics | 2 | 5.0 |
Homeodomain Proteins/genetics/*metabolism | 2 | 1.0 |
Trans-Activation (Genetics) | 2 | 0.0 |
Hela Cells | 3 | 0.0 |
Kinetics | 5 | 0.0 |
Recombinant Fusion Proteins/biosynthesis | 2 | 0.0 |
Bleomycin/administration & dosage | 3 | 4.0 |
Etoposide/administration & dosage | 2 | 1.0 |
Transplantation, Autologous | 2 | 0.0 |
Vinblastine/administration & dosage | 3 | 7.0 |
Chemical Warfare Agents/*toxicity | 3 | 50.0 |
Peritoneal Dialysis/*adverse effects | 2 | 13.0 |
Infant | 4 | 0.0 |
Receptor, Endothelin B | 2 | 3.0 |
Huntington Disease/*genetics/pathology | 3 | 60.0 |
*Trinucleotide Repeat Expansion | 3 | 6.0 |
*Polymorphism, Genetic | 2 | 0.0 |
*Body Composition | 3 | 2.0 |
Genes, Reporter | 2 | 0.0 |
Proteins/*metabolism | 2 | 0.0 |
Disease Susceptibility | 2 | 0.0 |
Biological Markers/analysis | 3 | 0.0 |
Cell Survival | 2 | 0.0 |
Exons | 5 | 0.0 |
Aging | 2 | 0.0 |
Guinea Pigs | 3 | 0.0 |
Isomerism | 2 | 0.0 |
Calcium/metabolism | 2 | 0.0 |
Drug Therapy, Combination | 2 | 0.0 |
*Peritoneal Dialysis | 2 | 3.0 |
Acute Disease | 2 | 0.0 |
Repetitive Sequences, Nucleic Acid | 4 | 0.0 |
Promoter Regions (Genetics)/genetics | 2 | 0.0 |
Transcription, Genetic/*physiology | 2 | 1.0 |
Neurons/*pathology | 2 | 3.0 |
Restriction Mapping | 4 | 0.0 |
Neuroblastoma | 2 | 1.0 |
Nuclear Proteins/genetics/metabolism | 3 | 1.0 |
Protein Binding/genetics | 3 | 1.0 |
Antibodies, Viral/*blood | 3 | 6.0 |
Parathyroid Hormone/blood | 3 | 1.0 |
Dialysis Solutions | 2 | 11.0 |
Hemodiafiltration/*methods | 2 | 40.0 |
Kidney Failure, Chronic/*blood/therapy | 2 | 3.0 |
*Environment | 3 | 6.0 |
Mice, Inbred Strains | 2 | 0.0 |
Desensitization, Immunologic/*methods | 2 | 20.0 |
Mites/*immunology | 2 | 4.0 |
Combined Modality Therapy | 3 | 0.0 |
Partial Thromboplastin Time | 2 | 1.0 |
Polymorphism, Genetic | 3 | 0.0 |
Structure-Activity Relationship | 2 | 0.0 |
Dacarbazine/administration & dosage | 2 | 16.0 |
Kidney Transplantation | 3 | 2.0 |
Sensitivity and Specificity | 4 | 0.0 |
Hepatitis B Surface Antigens/analysis | 2 | 3.0 |
Hepatitis Delta Virus/*immunology | 4 | 44.0 |
*Liver Transplantation | 2 | 1.0 |
Cell Division/drug effects | 3 | 0.0 |
Chromosome Mapping | 6 | 0.0 |
Immunophenotyping | 3 | 0.0 |
Temperature | 2 | 0.0 |
Renal Dialysis/*methods | 3 | 10.0 |
Genetic Markers | 4 | 0.0 |
Huntington Disease/diagnosis/*genetics | 2 | 66.0 |
*Trinucleotide Repeats | 2 | 1.0 |
Herpesvirus 4, Human/*isolation & purification | 2 | 5.0 |
Immunoenzyme Techniques | 3 | 0.0 |
Kidney Failure, Chronic/*complications | 2 | 5.0 |
Prevalence | 2 | 0.0 |
Great Britain | 2 | 0.0 |
Papio | 2 | 1.0 |
Hybrid Cells | 2 | 0.0 |
*Chromosomes, Human, Pair 4 | 5 | 2.0 |
*Linkage (Genetics) | 2 | 0.0 |
Epitopes/*immunology | 2 | 0.0 |
Neuraminic Acids/*immunology | 2 | 100.0 |
Monocytes/metabolism | 2 | 0.0 |
*Genetics, Population | 2 | 0.0 |
Gene Targeting | 2 | 0.0 |
Heterozygote | 3 | 0.0 |
Homozygote | 2 | 0.0 |
Randomized Controlled Trials | 2 | 0.0 |
Body Weight | 2 | 0.0 |
Hepatitis Antibodies/blood | 3 | 25.0 |
Hepatitis B Surface Antigens/blood | 2 | 7.0 |
Japan/epidemiology | 2 | 0.0 |
Antigens, Neoplasm/*analysis | 6 | 1.0 |
Chickens | 2 | 0.0 |
Antigens, Heterophile/*blood | 2 | 66.0 |
Carbohydrate Sequence | 2 | 0.0 |
Glycoproteins/immunology | 2 | 2.0 |
Radioimmunoassay | 4 | 0.0 |
Fatal Outcome | 2 | 0.0 |
Cell Movement/drug effects | 2 | 0.0 |
Keratinocytes/*drug effects | 2 | 11.0 |
Molecular Weight | 4 | 0.0 |
Hepatitis delta Antigens | 5 | 38.0 |
Hemoglobins/*metabolism | 2 | 4.0 |
Hodgkin Disease/*pathology | 2 | 16.0 |
Huntington Disease/*metabolism | 2 | 20.0 |
Evaluation Studies | 2 | 0.0 |
Antigens, Viral/*analysis | 2 | 4.0 |
Incidence | 2 | 0.0 |
Biological Transport | 2 | 0.0 |
Cell Division | 2 | 0.0 |
Blotting, Southern | 2 | 0.0 |
Cosmids | 2 | 0.0 |
Oligodeoxyribonucleotides | 2 | 0.0 |
Antigens, Heterophile/*analysis | 5 | 83.0 |
Chronic Disease | 2 | 0.0 |
Hydrogen-Ion Concentration | 3 | 0.0 |
Antigens, CD30 | 2 | 7.0 |
Polymorphism, Restriction Fragment Length | 3 | 0.0 |
Neuropsychological Tests | 2 | 0.0 |
Tomography, X-Ray Computed | 2 | 0.0 |
DNA Probes | 2 | 0.0 |
Carbon Radioisotopes | 2 | 2.0 |
Histidine Decarboxylase/*metabolism | 5 | 41.0 |
Tetradecanoylphorbol Acetate/pharmacology | 2 | 0.0 |
Glycoproteins/*blood | 2 | 2.0 |
Hepatitis B Vaccines | 2 | 33.0 |
Treatment Failure | 2 | 0.0 |
Viral Load | 2 | 0.0 |
Cell Survival/drug effects | 2 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 4 | 0.0 |
Species Specificity | 3 | 0.0 |
Kidney Failure, Chronic/*physiopathology | 2 | 13.0 |
Hepatitis Antibodies/*analysis | 2 | 28.0 |
Rats, Inbred Strains | 2 | 0.0 |
Lymphocyte Culture Test, Mixed | 2 | 0.0 |
Retinoblastoma/*immunology | 2 | 100.0 |
Clone Cells | 2 | 0.0 |
Leukocyte Count | 2 | 0.0 |
Carboxy-Lyases/*metabolism | 4 | 33.0 |
Antigens, Surface/*analysis | 4 | 2.0 |
Hodgkin Disease/*immunology | 4 | 14.0 |
Arrhythmia/etiology/*physiopathology | 2 | 66.0 |
Electrocardiography | 2 | 0.0 |
Kidney Failure, Chronic/complications/physiopathology/*therapy | 2 | 40.0 |
Long-Term Care | 2 | 3.0 |
Cytotoxicity Tests, Immunologic | 2 | 0.0 |
Administration, Oral | 2 | 0.0 |
Body Weight/drug effects | 3 | 1.0 |
Motor Activity/drug effects | 3 | 5.0 |
Enzyme Activation/drug effects | 2 | 0.0 |
